• Home
• About Us
  • Overview
  • Management
  • Board of Directors
  • Dynavax Europe
  • Careers
• Pipeline
  • Overview
  • HEPLISAV
  • Hepatitis B Therapy
  • Asthma
  • Autoimmunity / Inflammation
  • Flu Vaccine
• Partners
• Technology
  • Immune System
  • ISS
  • IRS
  • Publications
• Investors
  • Overview
  • News & Events
  • Stock Information
  • Analyst Coverage
  • Financials
  • SEC Filings
  • Corporate Governance
  • Contact Us
• Contact Us

Investors

• Overview
• News & Events
• Stock Information
• Analyst Coverage
• Financials
• SEC Filings
• Corporate Governance
  • Management
  • Board of Directors
  • Committee Composition
  • Contact the Board
• Contact Us

Overview

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com

Recent Press Releases May 9, 2012 Dynavax Prices Public Offering of Common Stock May 8, 2012 Dynavax Announces Proposed Public Offering of Common Stock View all releases » E-Delivery of Stockholder Communications Beneficial stockholders Registered stockholders

Corporate Presentation May 2012 Annual Report and Proxy 2012 Proxy Statement 2011 Form 10-K